Benitec Biopharm Financials

BNTC

Source SEC Filings (10-K/10-Q) Updated Feb 12, 2026 Currency USD FYE June

This page shows Benitec Biopharm (BNTC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

3/9

Benitec Biopharm passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.62x

For every $1 of reported earnings, Benitec Biopharm generates $0.62 in operating cash flow (-$23.6M OCF vs -$37.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Revenue

N/A

EBITDA

-$41.7M

YoY-86.1%

Benitec Biopharm's EBITDA was -$41.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 86.1% from the prior year.

Free Cash Flow

-$23.6M

YoY-20.5%

Benitec Biopharm generated -$23.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 20.5% from the prior year.

Net Income

-$37.9M

YoY-74.3%

Benitec Biopharm reported -$37.9M in net income in fiscal year 2025. This represents a decrease of 74.3% from the prior year.

EPS (Diluted)

$-1.05

YoY+13.9%

Benitec Biopharm earned $-1.05 per diluted share (EPS) in fiscal year 2025. This represents an increase of 13.9% from the prior year.

Cash & Debt

$97.7M

YoY+92.2%

5Y CAGR+58.4%

Benitec Biopharm held $97.7M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

26M

YoY+160.3%

Benitec Biopharm had 26M shares outstanding in fiscal year 2025. This represents an increase of 160.3% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$18.3M

YoY+17.4%

5Y CAGR+43.6%

Benitec Biopharm invested $18.3M in research and development in fiscal year 2025. This represents an increase of 17.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$18K

YoY-89.9%

5Y CAGR-28.3%

Benitec Biopharm invested $18K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 89.9% from the prior year.

BNTC Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	$0-100.0%	$75K+2.7%	$73K+23.7%	$59K-42.2%	$102K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$18.3M+17.4%	$15.6M+22.2%	$12.8M+13.3%	$11.3M+60.6%	$7.0M+133.9%	$3.0M
SG&A Expenses	$23.4M+235.3%	$7.0M+9.5%	$6.4M-4.0%	$6.6M+2.1%	$6.5M+17.0%	$5.6M
Operating Income	-$41.8M-85.7%	-$22.5M-17.9%	-$19.1M-6.9%	-$17.9M-31.3%	-$13.6M-64.2%	-$8.3M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$37.9M-74.3%	-$21.8M-11.2%	-$19.6M-7.4%	-$18.2M-31.2%	-$13.9M-67.8%	-$8.3M
EPS (Diluted)	$-1.05+13.9%	$-1.22	$-14.12	$-37.88-1072.8%	$-3.23	N/A

Metric	Q2'26	Q2'25	Q1'25	Q3'25	Q2'24	Q1'24	Q3'24	Q2'23
Revenue	N/A	$0	$0	$0	$0	$0	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$6K-99.9%	$5.8M+73.1%	$3.4M-43.6%	$6.0M+11.0%	$5.4M+50.2%	$3.6M+39.7%	$2.6M-49.7%	$5.1M
SG&A Expenses	$8K-99.9%	$7.5M+17.3%	$6.4M+52.9%	$4.2M-22.4%	$5.4M+145.7%	$2.2M+39.8%	$1.6M-13.5%	$1.8M
Operating Income	$13K+100.1%	-$13.4M-36.5%	-$9.8M+3.8%	-$10.2M+5.7%	-$10.8M-86.6%	-$5.8M-39.8%	-$4.1M+40.2%	-$6.9M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	$12K+100.1%	-$11.8M-32.0%	-$9.0M+4.2%	-$9.4M+2.1%	-$9.6M-88.8%	-$5.1M-18.2%	-$4.3M+37.1%	-$6.8M
EPS (Diluted)	$0.26+200.0%	$-0.26-18.2%	$-0.22+8.3%	$-0.24+7.7%	$-0.26-44.4%	$-0.18+21.7%	$-0.23	$-2.64

BNTC Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$99.6M+90.8%	$52.2M+1069.6%	$4.5M-25.3%	$6.0M-72.1%	$21.4M+84.5%	$11.6M
Current Assets	$98.5M+90.7%	$51.7M+1285.7%	$3.7M-22.6%	$4.8M-76.6%	$20.6M+90.7%	$10.8M
Cash & Equivalents	$97.7M+92.2%	$50.9M+1953.5%	$2.5M-39.0%	$4.1M-79.5%	$19.8M+101.7%	$9.8M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.3M-53.7%	$5.0M+16.4%	$4.3M+37.9%	$3.1M+125.8%	$1.4M+1.5%	$1.3M
Current Liabilities	$1.8M-63.4%	$4.9M+23.8%	$4.0M+57.1%	$2.5M+85.0%	$1.4M+20.5%	$1.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$97.3M+105.9%	$47.2M+23290.1%	$202K-93.0%	$2.9M-85.6%	$20.0M+95.4%	$10.2M
Retained Earnings	-$228.2M-19.9%	-$190.3M-13.3%	-$167.9M-13.2%	-$148.3M-14.0%	-$130.1M-11.6%	-$116.6M

Metric	Q2'26	Q2'25	Q1'25	Q3'25	Q2'24	Q1'24	Q3'24	Q2'23
Total Assets	$191K-99.9%	$190.7M+98.6%	$96.0M-8.7%	$105.2M+33.1%	$79.1M+15.0%	$68.8M+358.5%	$15.0M-29.8%	$21.4M
Current Assets	$190K-99.9%	$189.6M+99.4%	$95.1M-8.6%	$104.0M+32.1%	$78.7M+15.2%	$68.3M+375.7%	$14.4M-30.9%	$20.8M
Cash & Equivalents	$189K-99.9%	$188.8M+99.8%	$94.5M-8.8%	$103.6M+32.3%	$78.3M+15.4%	$67.8M+381.1%	$14.1M-30.8%	$20.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3K-99.9%	$3.3M+36.7%	$2.4M-68.2%	$7.6M+144.3%	$3.1M-31.9%	$4.6M+31.3%	$3.5M-40.5%	$5.9M
Current Liabilities	$3K-99.9%	$2.8M+38.3%	$2.0M-71.2%	$7.0M+127.5%	$3.1M-32.2%	$4.6M+32.5%	$3.4M-40.2%	$5.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$187K-99.9%	$187.4M+100.2%	$93.6M-4.1%	$97.6M+28.5%	$75.9M+18.3%	$64.2M+458.1%	$11.5M-25.7%	$15.5M
Retained Earnings	$249K+100.1%	-$249.0M-5.0%	-$237.1M-11.8%	-$212.0M-4.6%	-$202.7M-3.8%	-$195.3M-5.3%	-$185.5M-2.4%	-$181.3M

BNTC Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$23.6M-21.6%	-$19.4M-7.7%	-$18.0M-13.3%	-$15.9M-23.9%	-$12.8M-70.3%	-$7.5M
Capital Expenditures	$18K-89.9%	$179K+17800.0%	$1K-92.3%	$13K-94.1%	$221K+132.6%	$95K
Free Cash Flow	-$23.6M-20.5%	-$19.6M-8.7%	-$18.0M-13.2%	-$15.9M-21.9%	-$13.1M-71.1%	-$7.6M
Investing Cash Flow	-$18K+89.9%	-$179K-17800.0%	-$1K+92.3%	-$13K+94.1%	-$221K-135.1%	-$94K
Financing Cash Flow	$70.5M+3.6%	$68.0M+324.8%	$16.0M	N/A	$22.5M+1172.4%	$1.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q2'25	Q1'25	Q3'25	Q2'24	Q1'24	Q3'24	Q2'23
Operating Cash Flow	$7K+100.2%	-$3.8M-12.7%	-$3.4M-8.6%	-$3.1M+59.9%	-$7.7M-68.0%	-$4.6M+25.6%	-$6.2M-15.0%	-$5.4M
Capital Expenditures	$11	$0	N/A	$6K	$0	N/A	N/A	$1K
Free Cash Flow	$7K+100.1%	-$8.2M	N/A	-$3.1M+6.1%	-$3.3M	N/A	N/A	-$4.1M
Investing Cash Flow	$11+100.1%	-$11K	$0+100.0%	-$6K+50.0%	-$12K	$0+100.0%	-$179K	$0
Financing Cash Flow	$98K-99.9%	$98.2M	$0-100.0%	$28.4M+59.0%	$17.9M-17.5%	$21.7M	$0-100.0%	$39K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BNTC Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	-25441.3%-983.8pp	-24457.5%-1413.5pp	-23044.1%-14925.4pp	-8118.6%
Net Margin	N/A	N/A	-26082.7%-1140.2pp	-24942.5%-1413.7pp	-23528.8%-15417.1pp	-8111.8%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-38.1%+3.6pp	-41.7%+396.6pp	-438.2%-133.4pp	-304.8%-239.9pp	-64.9%+6.5pp	-71.4%
Current Ratio	54.67+44.2	10.49+9.6	0.94-1.0	1.90-13.1	15.05+5.5	9.52
Debt-to-Equity	0.02-0.1	0.10-21.0	21.10+20.0	1.07+1.0	0.07-0.1	0.13
FCF Margin	N/A	N/A	-24017.3%-2220.1pp	-21797.3%+326.5pp	-22123.7%-14643.3pp	-7480.4%

Metric	Q2'26	Q2'25	Q1'25	Q3'25	Q2'24	Q1'24	Q3'24	Q2'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	6.3%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	6.2%+12.4pp	-6.2%+3.1pp	-9.3%-0.4pp	-8.9%+3.2pp	-12.1%-4.7pp	-7.4%+21.2pp	-28.5%+3.3pp	-31.8%
Current Ratio	67.690.0	67.69+20.7	46.95+32.1	14.80-10.7	25.48+10.5	15.01+10.8	4.18+0.6	3.62
Debt-to-Equity	0.020.0	0.020.0	0.03-0.1	0.08+0.0	0.04-0.0	0.07-0.2	0.30-0.1	0.38
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

AUTOLUS THERAPEUTICS PLC AUTL

$372.6M

Larimar Therapeutics Inc LRMR

$261.7M

Galectin Therapeutics Inc GALT

$177.9M

Diamedica Therapeutics Inc DMAC

$444.2M

Adc Therapeutics Sa ADCT

$494.3M

Frequently Asked Questions

Is Benitec Biopharm profitable?

No, Benitec Biopharm (BNTC) reported a net income of -$37.9M in fiscal year 2025.

What is Benitec Biopharm's earnings per share (EPS)?

Benitec Biopharm (BNTC) reported diluted earnings per share of $-1.05 for fiscal year 2025. This represents a 13.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Benitec Biopharm's EBITDA?

Benitec Biopharm (BNTC) had EBITDA of -$41.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Benitec Biopharm's free cash flow?

Benitec Biopharm (BNTC) generated -$23.6M in free cash flow during fiscal year 2025. This represents a -20.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Benitec Biopharm's operating cash flow?

Benitec Biopharm (BNTC) generated -$23.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Benitec Biopharm's total assets?

Benitec Biopharm (BNTC) had $99.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Benitec Biopharm's capital expenditures?

Benitec Biopharm (BNTC) invested $18K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Benitec Biopharm spend on research and development?

Benitec Biopharm (BNTC) invested $18.3M in research and development during fiscal year 2025.

How many shares does Benitec Biopharm have outstanding?

Benitec Biopharm (BNTC) had 26M shares outstanding as of fiscal year 2025.

What is Benitec Biopharm's current ratio?

Benitec Biopharm (BNTC) had a current ratio of 54.67 as of fiscal year 2025, which is generally considered healthy.

What is Benitec Biopharm's debt-to-equity ratio?

Benitec Biopharm (BNTC) had a debt-to-equity ratio of 0.02 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Benitec Biopharm's return on assets (ROA)?

Benitec Biopharm (BNTC) had a return on assets of -38.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Benitec Biopharm's cash runway?

Based on fiscal year 2025 data, Benitec Biopharm (BNTC) had $97.7M in cash against an annual operating cash burn of $23.6M. This gives an estimated cash runway of approximately 50 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Benitec Biopharm's Piotroski F-Score?

Benitec Biopharm (BNTC) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Benitec Biopharm's earnings high quality?

Benitec Biopharm (BNTC) has an earnings quality ratio of 0.62x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.